UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-------- ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $26.2 million, a decrease of 20% from $32.8 million in Q3 2021, attributed to declining COVID-19 testing volumes and economic shutdowns in Asia [29][30] - Enzo Clinical Lab Service revenue was $18.6 million, down 26% from $25 million in the same quarter last year, although routine testing revenue increased by 10% [30] - Enzo Life Sciences revenue was $7.6 million, slightly down year-over-year but up 9% year-to-date, indicating stability in the customer base [32] Business Line Data and Key Metrics Changes - Enzo Clinical Lab's non-COVID revenue increased by 3% year-over-year, demonstrating recovery in core testing [30] - The company added 43 new tests in Q3, totaling 126 new tests year-to-date, focusing on specialty testing [31] - Enzo Life Sciences faced challenges due to economic shutdowns in Asia and supply chain issues in Europe, but anticipates overall annual growth of 10% for fiscal year 2022 [32] Market Data and Key Metrics Changes - The blended gross margin for the quarter declined to 39% from 49% year-over-year, impacted by both Enzo Clinical Lab and Enzo Life Sciences [33] - Enzo Clinical Lab's margin decreased from 49% to 40% due to reduced higher-margin COVID tests, while Life Sciences gross margin fell to 36% due to increased manufacturing costs [33][34] Company Strategy and Development Direction - The company is focused on a corporate structure that supports three separate businesses: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Diagnostics, which allows for synergies and tailored solutions [12][11] - Enzo is committed to investing in technology and strategic partnerships to accelerate growth in core life sciences and clinical lab businesses [19] - The company is preparing to launch new diagnostic platforms and has received approvals for several molecular tests, indicating a strong focus on expanding its diagnostic capabilities [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic vision and ability to execute on growth initiatives, particularly in Life Sciences and Diagnostic platforms [40][28] - The company is exploring strategic alternatives with the help of Jefferies LLC, indicating a proactive approach to enhancing shareholder value [39][28] Other Important Information - Cash and cash equivalents totaled $32.1 million as of April 30, 2022, down from $44.3 million at the end of fiscal year 2021, due to various strategic initiatives [37] - The company maintains a goal of achieving an additional $10 million in cost savings, with $5 million targeted for calendar year 2022 [38] Q&A Session Summary Question: Clarification on the Jefferies process and its differences from the prior process - Management indicated that they are not making public comments on the specifics but are picking up where they left off in the previous process [42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |-------------------------------------------------- ...

Enzo Biochem, Inc. (NYSE:ENZ) Q2 2022 Earnings Conference Call March 14, 2022 4:30 PM ET Company Participants David Holmes - Investor Relations Hamid Erfanian - Chief Executive Officer David Bench - Chief Financial Officer Conference Call Participants Paul Nouri - Noble Equity Fund Christian Schwab - Craig Hallum Kenan Lucas - Harbert Management Corporation Dan Weston - WestCap Management Operator Greetings. And welcome to the Enzo Biochem Second Quarter 2022 Financial Results and Business Update Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |------------------------------------------------ ...

Enzo Biochem, Inc. (NYSE:ENZ) Q1 2022 Results Conference Call December 15, 2021 4:30 PM ET Company Participants David Holmes - LifeSci Advisors IR Hamid Erfanian - CEO David Bench - CFO Conference Call Participants Paul Nouri - Noble Equity Fund Operator Greetings. Welcome to the Enzo Biochem First Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |------------------------------------------------ ...

Financial Performance - Revenues for the three months ended October 31, 2020, increased to $28.655 million, a 42% increase from $20.207 million in the same period of 2019[135] - Operating income improved to $497,000 for the three months ended October 31, 2020, compared to a loss of $8.203 million in the prior year[135] - Net income for the three months ended October 31, 2020, was $299,000, a significant recovery from a net loss of $7.648 million in the same period of 2019[135] Cost Management - Cost of revenues decreased by 15% to $16.758 million from $14.521 million year-over-year[135] - Research and development expenses decreased by 29% to $746,000 compared to $1.054 million in the prior year[135] - Selling, general, and administrative expenses decreased by 10% to $10.014 million from $11.139 million in the same period of 2019[135] - Legal and related expenses decreased significantly by 62% to $640,000 from $1.696 million year-over-year[135] Government Assistance - The company received approximately $750,000 from the CARES Act Relief Payment grant in April 2020 and another $750,000 in July 2020[124] Intellectual Property - Enzo has a substantial portfolio of 495 issued patents worldwide and 71 pending patent applications, enhancing its competitive position in the market[127] Future Outlook - Enzo anticipates improved profitability with increased service volume from the introduction of new molecular and esoteric tests[130] Clinical Services Performance - Clinical Services revenues for the 2021 period were $21.2 million, an increase of $8.4 million or 66% year-over-year compared to $12.8 million in 2020[138] - Diagnostic testing volume increased by 49% period over period due to COVID-19, contributing to the revenue increase in the 2021 period[138] - The gross profit margin on Clinical Services revenues improved to 39% in the 2021 period from 14% in the 2020 period[141] Product Revenues - Product revenues remained at $7.4 million for both the 2021 and 2020 periods, with declines in the U.S. market offset by increases in international markets[140] Cash Flow and Liquidity - Net cash used in operating activities decreased by approximately $0.9 million to $1.2 million in the fiscal 2021 period[150] - The Company had cash and cash equivalents of $45.9 million as of October 31, 2020, a decrease from $47.9 million at July 31, 2020[149] Accounts Receivable - As of October 31, 2020, approximately 70% of the Company's net accounts receivable relates to its Clinical Laboratory Services business[168] - The total net accounts receivable increased to $12.051 million as of October 31, 2020, from $9.141 million as of July 31, 2020, representing a growth of approximately 32.9%[170] - Clinical Services net receivables totaled $8.415 million as of October 31, 2020, with third-party payers contributing $3.990 million or 48%[170] - Foreign receivables for Life Science products accounted for $1.2 million or 33% of total receivables as of October 31, 2020[169] - Approximately 18% of Clinical Labs receivables are from one payer, indicating a concentration risk[172] Risk Management - The Company has not engaged in any hedging or market risk management tools, exposing it to foreign currency exchange rate risks[187] - A hypothetical 10% increase in the value of the U.S. dollar could decrease the Company's net sales by $1.0 million annually[188] - The Company has fixed interest rate financing on a building mortgage and equipment finance leases as of October 31, 2020[190] - The Company assesses the collectability of receivables based on the quality of its billing processes, which could impact future estimates[172] - The Company performs annual impairment tests for goodwill and long-lived assets, with potential risks from the COVID-19 pandemic[186]

Financial Data and Key Metrics Changes - Total revenue for Q1 2021 was $28.7 million, a 47% increase from the previous quarter and a 42% increase year-over-year from $20.2 million [7][16] - Consolidated gross margin improved to 42%, up from 28% in the year-ago period [16] - Positive EBITDA of over $1 million and net income of approximately $0.01 per share, compared to a loss of $3.3 million or negative $0.07 per share in the previous quarter [7][19] Business Line Data and Key Metrics Changes - Clinical services revenue increased 66% to $21.2 million from $12.8 million in Q1 2020, driven by volume growth to approximately 300,000 accessions [17] - Net revenue per accession grew to over $69 from $62 in Q1 2020, reflecting an improved testing mix [18] - Enzo Life Science gross margin was 49%, compared to 52% a year ago, with a 3% increase from the previous quarter [18] Market Data and Key Metrics Changes - The company expanded its operational capacity to meet the increased demand for COVID-19 testing, which has positively impacted revenue and margins [10][20] - The company has established partnerships with universities and local government entities for COVID-19 testing services, which are expected to transition into long-term opportunities [12] Company Strategy and Development Direction - Enzo aims to transform into an integrated end-to-end diagnostic products and solutions company, focusing on building infrastructure for growth and enhancing value in the diagnostic sector [9][21] - The company is expanding into new areas such as point of care and direct-to-consumer offerings, with plans to launch home testing kits for various diseases [10][13] - The addition of new independent directors with expertise in drug discovery and companion diagnostics is expected to enhance the company's capabilities in these areas [11][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to adapt to the ongoing challenges posed by COVID-19 and highlighted the importance of diagnostics in the future healthcare landscape [22][43] - The company anticipates continued demand for COVID-19 testing and serological tests to validate immunity post-vaccination [43] - Management emphasized the importance of maintaining operational efficiency and cost containment measures, which have contributed to margin improvements [32] Other Important Information - Cash and cash equivalents totaled $46 million as of October 31, 2020, slightly down from $48 million at the end of the fiscal year [20] - The company is committed to investing in key growth areas to expand its product and platform capabilities [20] Q&A Session Summary Question: How successful is the company in expanding or cross-selling core offerings to customers who initially had the COVID test? - Management noted that the SIT program has extended beyond COVID testing to include other health services, indicating a successful cross-selling strategy [24] Question: What is the update on the Farmingdale facility expansion? - The doubling of the facility's capacity is ongoing, with new machines and resources being added [27] Question: What dynamics drove the increase in the run rate revenue? - Management indicated that increased COVID testing and account growth contributed to the revenue increase, along with margin expansion from the molecular platform [31] Question: What is the strategy regarding companion diagnostics and liquid biopsy? - The company is focused on extending its capabilities into cancer diagnostics and drug discovery, leveraging its technology portfolio [34][35] Question: How is the company addressing supply shortages for diagnostic tests? - Management highlighted that vertical integration allows the company to manufacture most of its own reagents, providing a competitive edge despite ongoing supply chain challenges [39] Question: What are the company's priorities post-pandemic? - Management emphasized the need for ongoing COVID testing and the potential for new business opportunities in various sectors, including nursing homes and educational institutions [44]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 13-2866202 (State or ...